|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 | |
网站主页 >> 化工产品目录 >> 吉法吡酯>> 市场分析报告 |
吉法吡酯市场分析报告 |
|
Purinergic Receptor (Purinoceptor) Antagonists - Pipeline Insight, 2022 ... Receptor (Purinoceptor) Antagonists Emerging Drugs Gefapixant: Merck & Co Gefapixant, an investigational, orally administered, selective ... ’s New Drug Application (NDA) for gefapixant. Selatogrel: Idorsia Pharmaceuticals Selatogrel acts ... P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021 P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021 SUMMARY P2X Purinoceptor 3 (P2RX3) - P2X purinoceptor 3 is a protein encoded by the P2RX3 gene. It belongs to the family of purinoceptors. This receptor functions as a ligand-gated ion channel and ... Interstitial Cystitis - Pipeline Insight, 2021 ... Pharmaceuticals PureTech Health Key Products Gefapixant LYT 503 Fremanezumab Peppermint oil ... Expectorant Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) ... KGaA received FDA approval for Gefapixant, an investigational, orally administered, selective P2X3 ... receptor antagonist. Gefapixant is used as a potential treatment for refractory ... P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2018 P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2018 SUMMARY P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. The latest report P2X Purinoceptor 3 (P2RX3) - ... P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2019 P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2019 SUMMARY According to the recently published report 'P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2019'; P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 14 molecules. Out of which ... Obstructive Sleep Apnea - Pipeline Insight, 2021 ... AD109 ACT-541468 TAK-925 Gefapixant TS-142 BAY2586116 Seltorexant Dronabinol low ... P2X Purinoceptor 3 - Pipeline Review, H1 2020 P2X Purinoceptor 3 - Pipeline Review, H1 2020 SUMMARY According to the recently published report 'P2X Purinoceptor 3 – Pipeline Review, H1 2020'; P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 ... Sleep apnoea syndrome - Pipeline Insight, 2021 This report can be delivered to the clients within 48 Hours DelveInsight’s, “Sleep apnoea syndrome – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Sleep apnoea syndrome pipeline landscape. It ... Cough Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Cough Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cough - Drugs In Development, 2022, provides an overview of the ... Chronic Cough Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major chronic cough markets reached a value of US$ 4.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.38% during 2024-2034. The chronic cough market has been ... Chronic Refractory Cough Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major chronic refractory cough markets reached a value of US$ 9.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 14.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.74% during 2024-2034. The chronic refractory cough ... Cough Syrup Market Report by Product Type (Expectorants, Cough Suppressants/Antitussives, Combination Medications), Age Group (Pediatric, Adult), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), and Region 2025-2033 ... ’s new drug application (NDA) for gefapixant, one of the drugs to treat refractory ... Global P2X Purinoceptor 3 Market Research Report 2025(Status and Outlook) ... , including selective P2X3 inhibitors like gefapixant (for refractory chronic cough), highlight ... |